Brief: Cardiff Oncology To Present New Data From Lead Clinical Program In KRAS-Mutated Metastatic Colorectal Cancer On September 8, 2021
25/08/2021 13:28
Aug 25 (Reuters) - Cardiff Oncology Inc CRDF.O :
* CARDIFF ONCOLOGY TO PRESENT NEW DATA FROM LEAD CLINICAL
PROGRAM
IN KRAS-MUTATED METASTATIC COLORECTAL CANCER ON SEPTEMBER 8,
2021
Source text for Eikon: ID:nPn3Mbm3za
Further company coverage: CRDF.O
(((Reuters.Briefs@thomsonreuters.com);))
Recent news on Cardiff Oncology
See all newsBrief: Cardiff Oncology Receives FDA Orphan Drug Designation For Onvansertib In Chronic Myelomonocytic Leukemia
Corrected: Cardiff Oncology Q2 operating expenses fall on lower R&D costs
Cardiff Oncology Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Cintas, Veradermics
Cardiff Oncology sinks on direct equity offering